<DOC>
	<DOCNO>NCT00002388</DOCNO>
	<brief_summary>The purpose study see safe give 1592U89 HIV-infected patient . This study also examine effect 1592U89 plasma viral load ( level HIV blood ) .</brief_summary>
	<brief_title>A Study 1592U89 HIV-Infected Patients</brief_title>
	<detailed_description>Cohorts 8 patient enter sequentially 1 6 1592U89 dosing regimen . All patient receive 12 week monotherapy initial 12-week treatment phase . On completion treatment phase , patient offer continuation therapy 1592U89 minimum 12 week .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Prophylaxis opportunistic infection . Patients must : HIV1 infection . CD4 cell count 100 500 cells/mm3 within 3 5 week prior study drug administration . No active diagnosis AIDS ( nonvisceral Kaposi 's sarcoma ) accord 1993 CDC AIDS surveillance definition . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Malabsorption syndrome gastrointestinal dysfunction may interfere drug absorption . Chronic disease diabetes , congestive heart failure , cardiomyopathy , cardiac dysfunction opinion investigator , would compromise safety patient . Concurrent Medication : Excluded : Immunomodulating agent . Chemotherapeutic agent . Antiretroviral therapy . NOTE : Patients elect continue study treatment extended phase may , consultation primary physician , combine 1592U89 recommend dose 300 mg bid license antiretroviral drug . Concurrent Treatment : Excluded : Radiation therapy . Patients follow prior condition exclude : History clinically relevant hepatitis pancreatitis within 6 month prior study drug administration . History hypersensitivity , anaphylactic , idiosyncratic reaction nucleoside analog . Prior Medication : Excluded : Treatment immunomodulating cytotoxic chemotherapeutic agent within six week prior study drug administration . Antiretroviral therapy within 2 week prior administration study drug . Prior Treatment : Excluded : Radiation therapy within six week prior study drug administration . Current alcohol illicit control substance use opinion investigator , may interfere patient 's ability complete study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 1998</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
</DOC>